Keryx Biopharmaceuticals (KERX) Trading -1.5% Higher

Keryx Biopharmaceuticals (NASDAQ:KERX)’s share price traded up 1.5% during trading on Tuesday . The company traded as high as $4.94 and last traded at $4.65. 1,067,800 shares traded hands during trading, a decline of 31% from the average session volume of 1,547,099 shares. The stock had previously closed at $4.72.

A number of equities analysts recently commented on the stock. Zacks Investment Research cut shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 14th. Stifel Nicolaus dropped their price target on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating for the company in a research note on Wednesday, November 8th. Finally, ValuEngine cut shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, November 10th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $7.35.

The firm has a market capitalization of $585.39, a price-to-earnings ratio of -3.30 and a beta of 4.93. The company has a debt-to-equity ratio of 13.95, a quick ratio of 3.76 and a current ratio of 4.46.

Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). Keryx Biopharmaceuticals had a negative net margin of 323.92% and a negative return on equity of 10,954.62%. The company had revenue of $15.00 million for the quarter, compared to the consensus estimate of $18.88 million. During the same quarter in the previous year, the business earned ($0.39) EPS. The company’s quarterly revenue was up 138.1% compared to the same quarter last year. research analysts anticipate that Keryx Biopharmaceuticals will post -1.36 earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. UBS Asset Management Americas Inc. raised its holdings in shares of Keryx Biopharmaceuticals by 0.3% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 38,316 shares of the biopharmaceutical company’s stock valued at $277,000 after purchasing an additional 102 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Keryx Biopharmaceuticals by 0.3% in the 2nd quarter. Rhumbline Advisers now owns 99,711 shares of the biopharmaceutical company’s stock valued at $721,000 after purchasing an additional 335 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Keryx Biopharmaceuticals by 4.2% in the 2nd quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 590 shares in the last quarter. Parametric Portfolio Associates LLC raised its holdings in shares of Keryx Biopharmaceuticals by 0.6% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 194,227 shares of the biopharmaceutical company’s stock valued at $1,404,000 after purchasing an additional 1,245 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in shares of Keryx Biopharmaceuticals by 8.5% in the 2nd quarter. Legal & General Group Plc now owns 28,205 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 2,220 shares in the last quarter. Institutional investors and hedge funds own 64.82% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Keryx Biopharmaceuticals (KERX) Trading -1.5% Higher” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://transcriptdaily.com/2018/01/04/keryx-biopharmaceuticals-kerx-trading-1-5-higher.html.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply